Mind Medicine (MindMed) マネジメント

マネジメント基準チェック /44

Mind Medicine (MindMed)の CEO はRob Barrowで、 Jun2021年に任命され、の在任期間は 3.42年です。の年間総報酬は$ 2.14Mで、 27.9%給与と72.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.27%を直接所有しており、その価値は$ 1.52M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3.1年です。

主要情報

Rob Barrow

最高経営責任者

US$2.1m

報酬総額

CEO給与比率	27.9%
CEO在任期間	3.4yrs
CEOの所有権	0.3%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Apr 04

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Feb 02

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Oct 19

MindMed announces proposed public offering of common shares

Sep 27

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Sep 20

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Sep 14

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Sep 04

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Aug 26

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder

Aug 24

MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps

Aug 18

Mind Medicine GAAP EPS of -$0.04 beats by $0.01

Aug 11

CEO報酬分析

Mind Medicine (MindMed) の収益と比較して、Rob Barrow の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$102m
Mar 31 2024	n/a	n/a	-US$125m
Dec 31 2023	US$2m	US$599k	-US$96m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$63m
Dec 31 2022	US$5m	US$672k	-US$57m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$98m
Dec 31 2021	US$12m	US$350k	-US$93m

報酬と市場: Robの総報酬 ($USD 2.14M ) は、 US市場 ($USD 2.24M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rob Barrow (35 yo)

3.4yrs

在職期間

US$2,143,133

報酬

Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Barrow	CEO & Director	3.4yrs	US$2.14m	0.27% $ 1.5m
Daniel Karlin	Chief Medical Officer	3.8yrs	US$1.04m	0.32% $ 1.8m
Miriam Wernli	Executive President	4.3yrs	US$2.66m	0.16% $ 879.7k
Scott Freeman	Co-Founder & Clinical Advisor	no data	US$501.19k	データなし
Leonard Latchman	Co-founder	no data	データなし	データなし
Carrie Liao	VP & Chief Accounting Officer	2yrs	データなし	0.060% $ 332.9k
Mark Sullivan	Chief Legal Officer & Corporate Secretary	1.6yrs	データなし	0.072% $ 396.4k
Francois Lilienthal	Chief Commercial Officer	2.6yrs	データなし	データなし
Stephanie Fagan	Chief Corporate Affairs Officer	less than a year	データなし	データなし
Gregg Pratt	Chief Regulatory & Quality Assurance Officer	no data	データなし	データなし

2.3yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: MNMDの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Barrow	CEO & Director	2.9yrs	US$2.14m	0.27% $ 1.5m
Carol Vallone	Independent Chairperson	3.2yrs	US$196.20k	0.018% $ 98.7k
David Gryska	Independent Director	1.4yrs	US$179.01k	0.011% $ 61.0k
Suzanne Bruhn	Independent Director	2.3yrs	US$148.70k	0.017% $ 92.0k
Robert Malenka	Chair of Scientific Advisory Board	3.7yrs	データなし	データなし
Robert Dworkin	Member of Scientific Advisory Board	3.3yrs	データなし	データなし
Maurizio Fava	Member of Scientific Advisory Board	3.4yrs	データなし	データなし
Andreas Krebs	Independent Vice Chairman	3.2yrs	US$186.20k	0.016% $ 87.9k
Roger Crystal	Independent Director	2.3yrs	US$148.70k	0.017% $ 92.0k
Nzinga Harrison	Member of Scientific Advisory Board	less than a year	データなし	データなし
Peter Bergethon	Member of Scientific Advisory Board	3.4yrs	データなし	データなし
Maria Oquendo	Member of Scientific Advisory Board	3yrs	データなし	データなし

3.1yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: MNMDの取締役会は経験豊富であると考えられます ( 3.1年の平均在任期間)。

Mind Medicine (MindMed) マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

CEO & Director notifies of intention to sell stock

Executive President exercised options and sold US$81k worth of stock

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Chief Financial Officer recently sold US$76k worth of stock

Recent updates

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

New minor risk - Share price stability

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

CEO & Director notifies of intention to sell stock

Price target increased by 9.3% to US$26.50

Executive President exercised options and sold US$81k worth of stock

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 10% to US$28.67

Mind Medicine (MindMed) Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 7.5% to US$26.17

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New minor risk - Share price stability

Price target increased by 14% to US$25.83

Price target decreased by 36% to US$14.50

New major risk - Revenue and earnings growth

Price target increased by 14% to US$25.83

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold US$76k worth of stock

New minor risk - Share price stability

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Price target decreased by 11% to US$27.63

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

MindMed announces proposed public offering of common shares

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Price target decreased to US$51.10

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

マネジメント基準チェック /44